- Home
- BDX
as 02-21-2025 4:00pm EST
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures prefilled devices, diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Medical is nearly half of the total business, while BD Life Sciences (27% of 2024 revenue) and BD Interventional (24%) account for the remainder. International revenue accounts for 43% of the company's business.
| Founded: | 1897 | Country: | United States |
| Employees: | N/A | City: | FRANKLIN LAKES |
| Market Cap: | 64.5B | IPO Year: | 1962 |
| Target Price: | $278.29 | AVG Volume (30 days): | 2.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 5.94 | EPS Growth: | 41.25 |
| 52 Week Low/High: | $218.75 - $251.99 | Next Earning Date: | 02-05-2025 |
| Revenue: | $20,640,000,000 | Revenue Growth: | 5.89% |
| Revenue Growth (this year): | 9.97% | Revenue Growth (next year): | 4.84% |
Stock Insider Trading Activity of Becton Dickinson and Company (BDX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| SCOTT BERTRAM L | BDX | Director | Feb 12 '25 | Sell | $227.99 | 700 | $159,593.00 | 36,033 | |
| Neal Shana Carol | BDX | EVP and Chief People Officer | Jan 21 '25 | Sell | $240.00 | 787 | $188,880.00 | 15,414 | |
| Shan David | BDX | EVP and Chief ISC Officer | Jan 21 '25 | Sell | $240.00 | 500 | $120,000.00 | 5,741 | |
| Garrison Michael David | BDX | EVP & President, Medical | Jan 17 '25 | Sell | $236.51 | 597 | $141,196.47 | 5,544 | |
| Garrison Michael David | BDX | EVP & President, Medical | Dec 19 '24 | Sell | $223.33 | 2,838 | $633,810.54 | 5,544 | |
| Neal Shana Carol | BDX | EVP and Chief People Officer | Dec 6 '24 | Sell | $220.49 | 1,000 | $220,490.00 | 15,414 | |
| Goette Roland | BDX | EVP and President, EMEA | Dec 6 '24 | Sell | $220.02 | 5,121 | $1,130,528.97 | 14,217 | |
| Shan David | BDX | EVP and Chief ISC Officer | Dec 5 '24 | Sell | $220.25 | 1,500 | $330,375.00 | 5,741 |
Latest Becton Dickinson and Company News
BDX Breaking Stock News: Dive into BDX Ticker-Specific Updates for Smart Investing
MT Newswires
a day ago
Argus Adjusts Becton Dickinson and Co.'s Price Target to $270 From $290
Argus Research
a day ago
Analyst Report: Becton, Dickinson And Co.
Argus Research
a day ago
Market Digest: BDX, HLF, M, MAT, PWR, MDLZ, TWLO, BABA, FOXA
Medical Device Network
3 days ago
BD business separation could allow competitors to rise in IVD test markets
Zacks
4 days ago
Do Options Traders Know Something About BD (BDX) Stock We Don't?
MT Newswires
8 days ago
Barclays Adjusts Price Target on Becton, Dickinson and Company to $279 From $278
PR Newswire
9 days ago
BD to Present at Investor Healthcare Conferences
Zacks
10 days ago
Why Becton Dickinson (BDX) is a Top Growth Stock for the Long-Term
Compare BDX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BDX Becton Dickinson and Company - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.